...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer
【24h】

Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer

机译：Aldh1，Survivin和EpCAM联合分析在大肠癌中的临床预后价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Tumour aggressiveness might be related to the degree of main cancer hallmark acquirement of tumour cells, reflected by expression levels of specific biomarkers. We investigated the expression of Aldh1, Survivin, and EpCAM, together reflecting main cancer hallmarks, in relation to clinical outcome of colorectal cancer (CRC) patients.Methods: Immunohistochemistry was performed using a tumour tissue microarray of TNM (Tumour, Node, Metastasis)-stage I–IV CRC tissues. Single-marker expression or their combination was assessed for associations with the clinical outcome of CRC patients ( N =309).Results: Increased expression of Aldh1 or Survivin, or decreased expression of EpCAM was each associated with poor clinical outcome, and was therefore identified as clinically unfavourable expression. Analyses of the combination of all three markers showed worse clinical outcome, specifically in colon cancer patients, with an increasing number of markers showing unfavourable expression. Hazard ratios ranged up to 8.3 for overall survival ( P <0.001), 36.6 for disease-specific survival ( P <0.001), and 27.1 for distant recurrence-free survival ( P <0.001).Conclusions: Our data identified combined expression levels of Aldh1, Survivin, and EpCAM as strong independent prognostic factors, with high hazard ratios, for survival and tumour recurrence in colon cancer patients, and therefore reflect tumour aggressiveness.
机译：背景：肿瘤的侵袭性可能与特定细胞标志物表达水平所反映的肿瘤细胞主要癌症标志物获得程度有关。我们调查了Aldh1，Survivin和EpCAM的表达，共同反映了主要癌症标志与大肠癌（CRC）患者临床结局的关系。方法：使用TNM的肿瘤组织微阵列（肿瘤，淋巴结转移）进行免疫组织化学。 I-IV期CRC组织。评价了单标志物表达或其组合与CRC患者临床结局的相关性（N = 309）。结果：Aldh1或Survivin表达升高或EpCAM表达降低均与不良临床结局相关，因此被鉴定作为临床上不利的表达。所有三种标记物组合的分析显示出较差的临床结果，特别是在结肠癌患者中，并且越来越多的标记物显示出不利的表达。总体生存率的危险比最高为8.3（P <0.001），疾病特异性生存率的危险比最高为36.6（P <0.001），远距无复发生存的危险比最高为27.1（P <0.001）。结论：我们的数据确定了联合表达水平Aldh1，Survivin和EpCAM是结肠癌患者生存和肿瘤复发的强独立预后因素，具有较高的危险比，因此反映了肿瘤的侵袭性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号